## **Ustekinumab (Stelara) Treatment Plan for Gastroenterology**

□ None		
☐ Acetaminophen 650 r	ng PO	
☐ Diphenhydramine:	Dose: ☐ 25 mg ☐ 50 mg	Route: ☐ PO or ☐ IVP
$\  \   \square \   \text{Methylprednisolone:}$	Dose: $\square$ 40 mg or $\square$ 125	Route: IVP
☐ Famotidine:	Dose: 20 mg	Route: ☐ PO or ☐ IVPB
☐ Other (include drug, o	dose, and route):	
<b>Drug Orders:</b>		
☐ Induction: Ustekinum	ab (Stelara) (J3358) per 250 m	nL Sodium Chloride 0.9% IV to infuse over 1 hour for 1 dose
Dose: ☐ Weig	ht < 55 kg: 260 mg	
□ Weig	ht= 55-85 kg: 390 mg	
□ Weig	ht > 85 kg: 520 mg	
_		3 weeks following loading dose and coordinated by physician offic
Lab Orders:	mande dosing to be initiated e	weeks to nowing to during dose and coordinated by physician of the
Standing Orders:		
	tocol (CPOE-1396) will be actived and physician notified.	vated if any hypersensitivity reaction occurs, including anaphylaxi
Physician Signature:		Date:
Physician Name:		Phone:

## **Pre-Screening Requirements:**

- Provide TB screening results (PPD or QuantiFERON Gold Test) prior to start of therapy and within last 12 months
- Provide Hepatitis screening (Hepatitis B Surface Antigen) prior to start of therapy and within last 12 months

## **Previous Therapies:**

- For new patient referrals, please send history and physical and most recent physician note with completed plan
- If patient has previously received ustekinumab at another facility, please provide last date received: \_\_\_\_\_
- If patient has previously received another biologic therapy, please provide the name: \_\_\_\_\_

and the last date received: \_\_\_\_\_

## **Insurance/Authorization Information:**

Insurance Type:	
Insurance Authorization Reference Number:	
Date Obtained:	Authorization Valid Until:
Additional Notes:	

Fax completed Treatment Plan with authorization information to McLeod Infusion Services at the number below or call with any questions.

Seacoast: 843-366-2224 (Fax)

843-366-3626 (Phone)